Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability Study of New and Traditional SHR6390 Formulations
NCT04667156Phase 1Completed
- Sponsor
- Hengrui
- Start
- Dec 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dalpiciclib in breast cancer (6 arms), sponsored by Hengrui. Primary endpoints: Relative Bioavailability (Fr) at Day 35, Maximum Plasma Concentration (Cmax) at Day 35 and 2 more. Started Dec 2020; status: completed.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04667156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04667156.